Evidence map›Paper›PMID 36144563›Full record

ArticleMolecules (Basel, Switzerland)2022

Dosimetry of [

Kelly D Orcutt, Kelly E Henry, Christine Habjan, Keryn Palmer, Jack Heimann, Julie M Cupido, Vijay Gottumukkala, Derek D Cissell, Morgan C Lyon, Amira I Hussein and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. PreclinicalJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  2. A Phase 0 Imaging Trial of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  3. Review
  4. Article
  5. The molecular blueprint of targeted radionuclide therapy.Nature reviews. Clinical oncology · 2025
    Review
  6. EJNMMI radiopharmacy and chemistry · 2025
    Review
  7. Lead-it-EAZY! GMP-compliant production of [EJNMMI radiopharmacy and chemistry · 2024
    Article
  8. Influence of the Molar Activity ofPharmaceuticals (Basel, Switzerland) · 2023
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Kelly D OrcuttViewpoint Molecular Targeting, Inc., Coralville, IA 52241, USA.
Kelly E HenryInvicro, LLC, Needham, MA 02494, USA.
Christine HabjanInvicro, LLC, Needham, MA 02494, USA.
Keryn PalmerInvicro, LLC, Needham, MA 02494, USA.
Jack HeimannInvicro, LLC, Needham, MA 02494, USA.
Julie M CupidoInvicro, LLC, Needham, MA 02494, USA.
Vijay GottumukkalaInvicro, LLC, Needham, MA 02494, USA.
Derek D CissellInvicro, LLC, Needham, MA 02494, USA.ORCID 0000-0002-6450-422X
Morgan C LyonInvicro, LLC, Needham, MA 02494, USA.
Amira I HusseinInvicro, LLC, Needham, MA 02494, USA.
Dijie LiuViewpoint Molecular Targeting, Inc., Coralville, IA 52241, USA.
Mengshi LiViewpoint Molecular Targeting, Inc., Coralville, IA 52241, USA.ORCID 0000-0003-3398-0183
Frances L JohnsonViewpoint Molecular Targeting, Inc., Coralville, IA 52241, USA.
Michael K SchultzViewpoint Molecular Targeting, Inc., Coralville, IA 52241, USA.
Invicro (United States) · USViewpoint Molecular Targeting (United States) · USUniversity of Iowa · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0M
Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Jong Sung Kim · 1990 to 2026
$40.5M
Alpha-Particle Emitter Peptide Receptor Targeted Radionuclide Therapy for Neuroendocrine TumorsR01CA243014 · NCI · UNIVERSITY OF IOWA · PI MENDA, YUSUF · 2019 to 2024
$2.5M
GMP peptide manufacturing, pharmacology/toxicology, and scaled radionuclide production and validation for Pb-212 receptor targeted alpha-particle therapy clinical trials for metastatic melanoma.R44CA254613 · NCI · VIEWPOINT MOLECULAR TARGETING, INC. · PI SCHULTZ, MICHAEL KING · 2020 to 2021
$2.0M
Preclinical pharmacology, toxicology, biodistribution and dosimetry, and radionuclide production CMC validation for Pb-212 receptor targeted alpha-particle therapy for neuroendocrine tumors.R44CA250872 · NCI · VIEWPOINT MOLECULAR TARGETING, INC. · PI SCHULTZ, MICHAEL KING · 2020 to 2021
$2.0M
National Institute of Health NIH R01CA243014National Institute of Health R44CA250872National Institute of Health R44CA254613NCI NIH HHS R01 CA243014NCI NIH HHS R44 CA250872NCI NIH HHS R44 CA254613NIEHS NIH HHS P30 ES005605
6 · The paper itself

Abstract

[

Indexed as

MelanomaReceptor, Melanocortin, Type 1AnimalsChelating AgentsChloridesHumansLeadLigandsMiceThallium RadioisotopesTissue DistributionChelating AgentsChloridesLeadLigandsReceptor, Melanocortin, Type 1Thallium Radioisotopes203Pb208Tl212Pbabsorbed dosedosimetryMC1Rmelanoma

Identifiers

PMID36144563
PMCPMC9504749
OpenAlexW4296137091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.